Sandoz Can Sell First U.S. Biosimilar on September 2

Source: WSJ

Jul 24, 2015

A federal appeals court ruled that Novartis' Sandoz can begin selling the first biosimilar in the U.S. on Sept. 2, 2015.

Sandoz has been locked in a court battle over selling its Zarxio treatment -- a biosimilar version of Amgen's best-selling Neupogen.

The court battle has involved complex interpretation of the Biologics Price Competition and Innovation Act. A key issue disputed was was whether Sandoz was required to provide Amgen with a complete copy of its biosimilar application.

Court rulings thus far have indicated that brand-name drug makers will be far less able to delay biosimilars through court procedures while they search for patent infringements.

Read the WSJ blog

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments